- Home
- LVLU vs EVAX Comparison
LVLU vs EVAX Comparison
Compare LVLU & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | EVAX |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.6M | 31.9M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LVLU | EVAX |
|---|---|---|
| Price | $9.03 | $4.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 10.8K | ★ 23.9K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,284,000.00 | N/A |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | N/A | $328.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.22 | $1.25 |
| 52 Week High | $32.32 | $12.15 |
Technical Indicators
Market Signals| Indicator | LVLU | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 30.82 | 56.21 |
| Support Level | $3.87 | $2.64 |
| Resistance Level | $16.56 | $4.64 |
| Average True Range (ATR) | 1.10 | 0.31 |
| MACD | -0.36 | 0.03 |
| Stochastic Oscillator | 12.01 | 60.83 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About EVAX Evaxion Biotech
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.